Apotex Inc.

Apotex Pharmachem Inc.

Other

Prabhudas Bodhuri

Gamini Weeratunga

Boris Gorin

Avedis Karadeolian

Melanie R A Green

Stuart P Green

Eduardo Gustavo Cammisa

Alfredo Paul Ceccarelli

Michael R Emmett

Gamimi Weeratunga

Fabio E S Souza

Yajun Zhao

Fan Wang

Cameron L McPhail

Keshava K S Murthy

Kaarina K Milnes

The present invention provides processes for the preparation of Tezacaftor, as well as intermediates useful in the preparation thereof. In particular, processes are provided for the preparation of a compound of Formula (3), and its conversion to Tezacaftor (1). 

Processes for the preparation of Tezacaftor and intermediates thereof

The present invention provides processes for the preparation of Acalabrutinib (1), as well as intermediates useful in the preparation thereof. In particular, processes are provided for coupling of a compound of Formula (5) and 2-butynoic acid in the presence of Carbodiimide (8) to afford Acalabrutinib (1). 

Process for the preparation of acalabrutinib

The present invention provides processes for the preparation of Veliparib (1), as well as intermediates useful in the preparation thereof. In particular, processes are provided for the production of the compound of Formula (3), or a salt thereof, and cyclization to afford Veliparib (1). 

Processes for the preparation of Veliparib and intermediates thereof

The present invention provides processes for the preparation of Apalutamide (1), as well as intermediates useful in the preparation thereof. In particular, the process of the invention utilizes the intermediate compound of Formula (2), wherein G is OH or a leaving group, which provides improvements over the known processes for the preparation of Apalutamide (1). 

Processes for the preparation of apalutamide and intermediates thereof

The present invention provides processes for the preparation of Lesinurad (1), as well as intermediates useful in the preparation thereof. In particular, the processes of the invention utilize novel intermediate compounds of Formulas (3) and (11), which provide improvements over the known processes for the preparation of Lesinurad (1). 

Processes for the preparation of lesinurad and intermediates thereof

The present invention provides processes for the preparation of Edoxaban (1) and salts thereof, as well as intermediates thereof. In particular, intermediate compounds and/or salts of the Formulae (3), (4), (6-A), (7-A), (8-A), (9-A) and (10-AS) are provided.

Processes for the preparation of edoxaban and intermediates thereof

Solid and crystalline forms of tofacitinib hydrochloride and tofacitinib hydrobromide, processes for the preparation thereof and processes for the use thereof in preparing tofacitinib citrate are provided.

Solid forms of tofacitinib salts

There is provided crystalline solvate forms of Warfarin potassium, termed APO-I and APO-II, and processes for making APO-I and APO-II. APO-I and APO-II are polymorphic solvate forms of Warfarin potassium.

Polymorphic forms of Warfarin potassium and preparations thereof

Provided are process for the preparation of (R)- and/or (S)-Rivaroxaban, and compounds which are intermediate compounds used in the processes for the preparation of (R)- and/or (S)-Rivaroxaban.

Processes for the preparation of rivaroxaban and intermediates thereof

This invention provides a process for the preparation of S-Rivaroxaban and/or R-Rivaroxaban comprising reacting, in the presence of a first base, a compound of Formula 9: with a compound of Formula 8: 

Growing community of inventors

Brantford, Canada

Prabhudas Bodhuri